As neurodegenerative diseases continue to rise globally, researchers are turning to more physiologically relevant preclinical systems to close the translational gap that has long hindered CNS drug development. Alzheimer's disease alone affects more than 40 million people worldwide, and Parkinson's disease remains the second most common neurodegenerative disorder. Yet despite decades of investment, disease‑modifying therapies remain elusive. A new generation of in vitro and ex vivo models is beginning to reshape how the field approaches early discovery, mechanistic studies, and drug screening.

One area seeing rapid innovation is Alzheimer's disease modeling. While conventional 2D cultures and exogenous Aβ challenges provided early insights, they often fail to mirror the spatiotemporal complexity of progressive pathology. Newer 3D systems—ranging from neurospheroids to iPSC‑derived cortical organoids—capture hallmark features such as amyloid‑beta accumulation, tauopathy, neuroinflammation, and neuronal loss in a more human‑relevant context. These models allow researchers to probe early pathogenic cascades, evaluate candidate therapeutics, and study patient‑specific biology with unprecedented resolution. Creative Biolabs, for example, has developed a suite of customizable AD models spanning engineered cell lines, primary cultures, and complex organoids, enabling tailored approaches for diverse research questions.

Parkinson's disease research is undergoing a similar shift. While animal models remain indispensable for behavioral studies, no single animal system fully replicates the selective vulnerability of dopaminergic neurons or the progressive formation of Lewy body pathology. In vitro models—particularly those derived from iPSCs—are filling this gap by enabling controlled interrogation of mitochondrial dysfunction, α‑synuclein aggregation, oxidative stress, and dopamine handling. Midbrain organoids derived from patient cells now allow scientists to track developmental trajectories, assess neuronal vulnerability, and test neuroprotective strategies in a human‑specific environment. Creative Biolabs also supports PD research with customizable cell models, functional assays, and molecular analyses that help teams dissect disease mechanisms and evaluate therapeutic hypotheses.

Across both AD and PD pipelines, one barrier remains universal: the blood–brain barrier (BBB). Its selective permeability protects the CNS but also blocks most drug candidates. As a result, BBB modeling has become a critical component of CNS drug development. Modern BBB platforms now include endothelial monolayers, ECM‑based 3D co‑cultures, microfluidic “BBB‑on‑a‑chip” systems, and even 3D‑printed dynamic devices. These models allow researchers to quantify TEER, evaluate transport mechanisms, assess drug penetration, and simulate disease‑related barrier dysfunction. Creative Biolabs offers customizable BBB systems built from iPSC‑derived endothelial cells, astrocytes, and pericytes, providing a versatile platform for permeability studies, neurotoxicity testing, and disease modeling.

Together, these advances signal a broader shift toward human‑centered neuroscience research. By integrating disease‑specific organoids, mechanistic cell models, and physiologically relevant BBB systems, the field is building a more predictive preclinical ecosystem—one that may finally accelerate the path toward effective therapies for devastating neurodegenerative diseases.